CEO Joseph Tucker, Ph.D., to deliver company
presentation and participate in panel discussion
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
depression, anxiety, and addiction disorders, announced that Joseph
Tucker, Ph.D., Chief Executive Officer, will present at the
Centurion One 5th Global Summit being held on October 24-25, 2023
in Nassau, Bahamas.
Details of the presentations are as follows:
Presentation Format:
Company Presentation
Date:
Wednesday, October 25, 2023
Time:
11:40 AM ET
Location:
Grand Salon 2, Rosewood Baha Mar
Presentation Format:
“Unlocking Value in a Changing Landscape”
Panel
Date:
Wednesday, October 25, 2023
Time:
2:10 p.m. ET
Location:
Grand Salon 2, Rosewood Baha Mar
During the conference, Dr. Tucker will host individual
one-on-one meetings with registered investors, showcasing Enveric’s
business and clinical development strategy, recent corporate
achievements, and anticipated milestones.
Centurion One 5th Bahamas Global Summit will feature public and
private companies across various industries that will be given the
opportunity to present to some of the most prominent venture
capital, family office, private equity firms, high net worth
individuals and institutional investors in the growth space
attending from Canada, the United States, and abroad. For
registration details, please visit:
https://www.eventbrite.com-centurion-one-bahamas-summit.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of New Chemical Entities for
specific mental health indications. Enveric’s lead program, the
EVM201 Series, comprises next generation synthetic prodrugs of the
active metabolite, psilocin. Enveric is developing the first
product from the EVM201 Series – EB-373 – for the treatment of
psychiatric disorders. Enveric is also advancing its second
program, the EVM301 Series, expected to offer a first-in-class, new
approach to the treatment of difficult-to-address mental health
disorders, mediated by the promotion of neuroplasticity without
also inducing hallucinations in the patient. Enveric is
headquartered in Naples, FL with offices in Cambridge, MA and
Calgary, AB Canada. For more information, please visit
www.enveric.com.
About Centurion One Capital
Centurion One Capital (“Centurion One”) is the premier
independent Investment Banking firm dedicated to fueling the growth
and success of growth companies in North America. With an
unwavering commitment to delivering comprehensive financial
solutions and strategic guidance, Centurion One is a trusted
strategic partner and catalyst to propel issuers to unlock their
full potential. Centurion One’s team comprises of seasoned
professionals who combine extensive financial expertise with deep
knowledge of various sectors. Centurion One takes a proactive and
results-driven approach, working closely with our clients to
develop tailored strategies and execute transactions that maximize
value and drive long-term success.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposed,” “is expected,” “budgets,”
“scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, would, or might
occur or be achieved. Forward-looking statements may include
historical statements and statements regarding beliefs, plans,
expectations, or intentions regarding the future and are based on
the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not
limited to, the ability of Enveric to: carry out successful
clinical programs in Australia; achieve the value creation
contemplated by technical developments; avoid delays in planned
clinical trials; establish that potential products are efficacious
or safe in preclinical or clinical trials; establish or maintain
collaborations for the development of therapeutic candidates;
obtain appropriate or necessary governmental approvals to market
potential products; obtain future funding for product development
and working capital on commercially reasonable terms; scale-up
manufacture of product candidates; respond to changes in the size
and nature of competitors; hire and retain key executives and
scientists; secure and enforce legal rights related to Enveric’s
products, including patent protection; identify and pursue
alternative routes to capture value from its cannabinoid clinical
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231020004309/en/
Investor Relations Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (862) 213-1398
dboateng@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc.
Casey McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Apr 2024 to May 2024
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From May 2023 to May 2024